The Beauty Health Company (SKIN) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2022
Loading P/E history...
SKIN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, The Beauty Health Company (SKIN) trades at a price-to-earnings ratio of -5.8x, with a stock price of $0.93 and trailing twelve-month earnings per share of $-0.07.
The current P/E is 114% below its 5-year average of 40.9x. Over the past five years, SKIN's P/E has ranged from a low of 0.2x to a high of 89.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Consumer Defensive sector median P/E of 19.6x, SKIN trades at a 130% discount to its sector peers. The sector includes 149 companies with P/E ratios ranging from 0.0x to 193.7x.
Relative to the broader market, SKIN trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SKIN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SKIN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 32.0 | 0.79 | -13% | |
| $3B | 18.1 | 0.53 | +2% | |
| $354M | 2.3Lowest | - | +208%Best | |
| $369M | 34.5 | - | -74% | |
| $861M | 9.5 | 0.96 | -36% | |
| $24B | 20.9 | 0.40Best | +1% | |
| $1B | 7.4 | 0.54 | +32% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SKIN Historical P/E Data (2020–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $9.10 | $0.28 | 32.7x | -20% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $11.79 | $0.13 | 89.9x | +120% |
| FY2020 Q4 | $11.31 | $51.57 | 0.2x | -99% |
Average P/E for displayed period: 40.9x
See SKIN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKIN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKIN vs WMT
Side-by-side business, growth, and profitability comparison vs Walmart Inc..
Start ComparisonSKIN — Frequently Asked Questions
Quick answers to the most common questions about buying SKIN stock.
Is SKIN stock overvalued or undervalued?
SKIN trades at -5.8x P/E, below its 5-year average of 40.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SKIN's valuation compare to peers?
The Beauty Health Company P/E of -5.8x compares to sector median of 19.6x. The discount suggests lower growth expectations or higher risk.
What is SKIN's PEG ratio?
SKIN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2022.